NeuroSync Medical Receives FDA Breakthrough Designation for Spinal Cord Neural Bypass Device

Singapore / Washington D.C., November 10, 2027 — NeuroSync Medical, a four-year-old startup spun out of the National University of Singapore, has received FDA Breakthrough Device Designation for SyncBridge—a neural bypass implant designed to restore voluntary limb movement in patients with complete spinal cord injuries.

The SyncBridge system works by implanting two microelectrode arrays: one above the injury site to capture motor cortex signals, and one below to stimulate targeted muscle groups directly. A palm-sized processing unit worn on the hip decodes neural intent in real time and routes it around the injury site, effectively creating a digital bypass of the damaged spinal cord.

In a 42-patient clinical trial conducted across Singapore, Germany, and the United States, 78% of participants regained the ability to perform functional hand movements—such as gripping a cup or using a fork—within 12 weeks of calibration. The device does not repair the spinal cord itself; it routes around the injury, meaning results persist as long as the implant remains functional.

"This is not a cure. It is a bridge," said Dr. Lim Jiawei, NeuroSync's co-founder and chief medical officer. "Patients regain independence in activities of daily living. Some have returned to desk jobs they hadn't been able to perform in years."

The company plans to file its Premarket Approval (PMA) application with the FDA by mid-2028, targeting a US launch in 2029 at an estimated cost of $180,000 per implant. NeuroSync has raised $340 million to date, backed by Sequoia Capital Southeast Asia and GV.

Analysts note that SyncBridge enters a field that includes Elon Musk's Neuralink (which targets similar indications with a more invasive brain-spine interface) and Synchron's Stentrode (an endovascular approach). NeuroSync believes its minimally invasive approach and faster calibration time give it a competitive edge.